Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $83.59 million
- Book Value:
- Revenue TTM:
- $3.11 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Neovasc Inc had its IPO on 2007-02-05 under the ticker symbol NVCN.
The company operates in the Healthcare sector and Medical Devices industry. Neovasc Inc has a staff strength of 0 employees.
Shares of Neovasc Inc opened at $30.03 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $30.03 - $30.03, and closed at $30.03.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Neovasc Inc have increased by 0%.
Neovasc Inc's Key Ratios
Neovasc Inc has a market cap of $83.59 million, indicating a price to book ratio of 0.9983 and a price to sales ratio of 9.3708.
In the last 12-months Neovasc Inc’s revenue was $3.11 million with a gross profit of $-7076980 and an EBITDA of $-30968452. The EBITDA ratio measures Neovasc Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Neovasc Inc’s operating margin was 0% while its return on assets stood at -32.95% with a return of equity of -78.25%.
In Q4, Neovasc Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 31.3%.
Neovasc Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-15.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neovasc Inc’s profitability.
Neovasc Inc stock is trading at a EV to sales ratio of 2.8815 and a EV to EBITDA ratio of -0.1193. Its price to sales ratio in the trailing 12-months stood at 9.3708.
Neovasc Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $38.73 million
- Total Liabilities
- $10.07 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Neovasc Inc ended 2023 with $38.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $38.73 million while shareholder equity stood at $15.84 million.
Neovasc Inc ended 2023 with $0 in deferred long-term liabilities, $10.07 million in other current liabilities, 441369134.00 in common stock, $-463192850.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.79 million and cash and short-term investments were $25.79 million. The company’s total short-term debt was $219,522 while long-term debt stood at $12.63 million.
Neovasc Inc’s total current assets stands at $29.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.50 million compared to accounts payable of $2.18 million and inventory worth $1.09 million.
In 2023, Neovasc Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Neovasc Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Neovasc Inc stock is currently trading at $30.03 per share. It touched a 52-week high of $30.07 and a 52-week low of $30.07. Analysts tracking the stock have a 12-month average target price of $24.
Its 50-day moving average was $29.29 and 200-day moving average was $15.11 The short ratio stood at 0.94 indicating a short percent outstanding of 0%.
Around 369% of the company’s stock are held by insiders while 787.2% are held by institutions.
Frequently Asked Questions About Neovasc Inc
Similar Industry Stocks (Medical Devices)
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. As of April 11, 2023, Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc.